Free Trial
→ You’re Being LIED To About The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free CMND Stock Alerts

Clearmind Medicine (CMND) Competitors

Clearmind Medicine logo
$0.61 -0.06 (-9.56%)
Closing price 04:00 PM Eastern
Extended Trading
$0.61 0.00 (-0.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CMND vs. SXTP, VIVS, SPRC, ENTO, and SNGX

Should you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include 60 Degrees Pharmaceuticals (SXTP), VivoSim Labs (VIVS), SciSparc (SPRC), Entero Therapeutics (ENTO), and Soligenix (SNGX). These companies are all part of the "pharmaceutical products" industry.

How does Clearmind Medicine compare to 60 Degrees Pharmaceuticals?

Clearmind Medicine (NASDAQ:CMND) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Clearmind Medicine has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -550.67%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
60 Degrees Pharmaceuticals -550.67%N/A -132.47%

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Clearmind Medicine has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500.

Clearmind Medicine has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
60 Degrees Pharmaceuticals$1.41M3.09-$7.36M-$13.88N/A

In the previous week, Clearmind Medicine had 1 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 3 mentions for Clearmind Medicine and 2 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.49 beat Clearmind Medicine's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearmind Medicine
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

60 Degrees Pharmaceuticals has a consensus price target of $14.10, indicating a potential upside of 754.55%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Clearmind Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
60 Degrees Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

60 Degrees Pharmaceuticals beats Clearmind Medicine on 9 of the 15 factors compared between the two stocks.

How does Clearmind Medicine compare to VivoSim Labs?

Clearmind Medicine (NASDAQ:CMND) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
VivoSim Labs
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Clearmind Medicine has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. VivoSim Labs' return on equity of -15.51% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
VivoSim Labs -861.27%-15.51%-11.31%

Clearmind Medicine has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500.

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 2.5% of VivoSim Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

VivoSim Labs has higher revenue and earnings than Clearmind Medicine. VivoSim Labs is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
VivoSim Labs$140K26.47-$2.48M-$3.15N/A

In the previous week, Clearmind Medicine had 3 more articles in the media than VivoSim Labs. MarketBeat recorded 3 mentions for Clearmind Medicine and 0 mentions for VivoSim Labs. VivoSim Labs' average media sentiment score of 0.28 beat Clearmind Medicine's score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company Overall Sentiment
Clearmind Medicine Neutral
VivoSim Labs Neutral

Summary

VivoSim Labs beats Clearmind Medicine on 9 of the 13 factors compared between the two stocks.

How does Clearmind Medicine compare to SciSparc?

Clearmind Medicine (NASDAQ:CMND) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
SciSparc
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

SciSparc's return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
SciSparc N/A N/A N/A

Clearmind Medicine has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 2.71, indicating that its share price is 171% more volatile than the S&P 500.

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 25.1% of SciSparc shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Clearmind Medicine has higher earnings, but lower revenue than SciSparc.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A
SciSparc$860K3.21-$12.18MN/AN/A

In the previous week, Clearmind Medicine had 1 more articles in the media than SciSparc. MarketBeat recorded 3 mentions for Clearmind Medicine and 2 mentions for SciSparc. SciSparc's average media sentiment score of 0.54 beat Clearmind Medicine's score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Clearmind Medicine
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
SciSparc
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

SciSparc beats Clearmind Medicine on 7 of the 10 factors compared between the two stocks.

How does Clearmind Medicine compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:ENTO) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

12.3% of Entero Therapeutics shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Clearmind Medicine's return on equity of -207.53% beat Entero Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entero TherapeuticsN/A -461.02% -14.72%
Clearmind Medicine N/A -207.53%-100.70%

Entero Therapeutics is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entero TherapeuticsN/AN/A-$18.06M-$1.69N/A
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entero Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Entero Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

In the previous week, Clearmind Medicine had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Clearmind Medicine and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 equaled Clearmind Medicine'saverage media sentiment score.

Company Overall Sentiment
Entero Therapeutics Neutral
Clearmind Medicine Neutral

Summary

Entero Therapeutics and Clearmind Medicine tied by winning 5 of the 10 factors compared between the two stocks.

How does Clearmind Medicine compare to Soligenix?

Soligenix (NASDAQ:SNGX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Clearmind Medicine's return on equity of -207.53% beat Soligenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SoligenixN/A -241.06% -129.82%
Clearmind Medicine N/A -207.53%-100.70%

Soligenix has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Clearmind Medicine has lower revenue, but higher earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soligenix$120K27.33-$11.08M-$3.60N/A
Clearmind MedicineN/AN/A-$3.86M-$19.72N/A

3.6% of Soligenix shares are held by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are held by institutional investors. 3.1% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,786.20%. Given Soligenix's stronger consensus rating and higher possible upside, equities research analysts plainly believe Soligenix is more favorable than Clearmind Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Soligenix had 2 more articles in the media than Clearmind Medicine. MarketBeat recorded 5 mentions for Soligenix and 3 mentions for Clearmind Medicine. Clearmind Medicine's average media sentiment score of 0.00 beat Soligenix's score of -0.31 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Soligenix
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Clearmind Medicine
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Soligenix beats Clearmind Medicine on 8 of the 14 factors compared between the two stocks.

Get Clearmind Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMND vs. The Competition

Export
MetricClearmind MedicineMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.01M$3.09B$6.25B$11.77B
Dividend YieldN/A1.92%2.74%5.26%
P/E Ratio-0.0318.3729.2527.07
Price / SalesN/A278.28504.6873.47
Price / CashN/A55.2543.3053.90
Price / Book0.424.309.676.69
Net Income-$3.86M$72.19M$3.55B$332.64M
7 Day Performance-17.21%2.03%1.70%2.01%
1 Month Performance-43.47%6.42%5.62%9.19%
1 Year Performance-98.47%37.74%34.42%39.59%

Clearmind Medicine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMND
Clearmind Medicine
0.3454 of 5 stars		$0.61
-9.6%		N/AN/A$1.01MN/AN/AN/A
SXTP
60 Degrees Pharmaceuticals
1.9377 of 5 stars		$1.57
-1.9%		$14.10
+798.1%		N/A$4.15M$1.41MN/A3
VIVS
VivoSim Labs
0.8686 of 5 stars		$1.44
-3.4%		N/AN/A$3.76M$142KN/A20
SPRC
SciSparc
0.5755 of 5 stars		$9.03
+8.3%		N/AN/A$3.61M$1.31MN/A4
ENTO
Entero Therapeutics
N/A$2.24
-0.4%		N/AN/A$3.56MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMND) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel